Education
About Us
Working with TipRanks
Follow Us
Aspen Pharmacare (APNHY)
OTHER OTC:APNHY
Top Page
Aspen Pharmacare
(OTC:APNHY)
Select Model
Select Model
Rating:58Neutral
Price Target:
$8.50
▲(25.00% Upside)
Action:ReiteratedDate:03/04/26
The score is held back primarily by weak financial performance (declining revenue, negative profitability, and severely weaker free cash flow), partially offset by a strong technical uptrend. The earnings call adds moderate support due to improving cash metrics and the APAC divestment/deleveraging plan, while valuation remains constrained by a negative P/E and only modest dividend yield.
Positive Factors
Commercial Pharma margins
A high‑margin Commercial Pharma division showing mid‑single digit revenue growth and double‑digit EBITDA expansion provides durable earnings resilience. Stable ~29% EBITDA margins concentrate profit generation in a less cyclical, branded/retail channel, supporting cash flow and reinvestment over the medium term.
Improving cash & APAC divestment
Substantial operating cash generation plus a planned APAC disposal that could eliminate most net debt materially strengthens liquidity and deleverages the balance sheet. This structural improvement increases financial flexibility for capex, restructuring, and reduces interest burden over multiple quarters.
Product momentum & recovery pipeline
Growing GLP‑1 franchise and planned generic launches create sustainable commercial tailwinds. Combined with insulin ramp, RFQs in France and targeted sterile recovery actions, these durable product and contract wins can rebuild higher‑margin volumes and restore manufacturing returns over 2–3 years.
Negative Factors
Manufacturing & sterile collapse
The loss of a major mRNA contract and resulting ~85% EBITDA drop in Manufacturing is structural, revealing contract concentration and operational risk. Persistent underutilization and restructuring needs can depress margins and ROIC for multiple reporting periods until new contracts and sterile profitability are secured.
Weak cash conversion
Severely weakened free cash flow conversion signals impaired cash generation quality; an OCF/NI ratio of 0.29 and near‑zero FCF/NI leave little buffer for investment or debt paydown. Sustained weak cash conversion constrains strategic flexibility and elevates refinancing and execution risk over the medium term.
Elevated leverage & ROIC weakness
High net debt and acknowledged ROIC deterioration indicate capital is not generating expected returns. Until divestment proceeds are realized and ROIC trends reverse, elevated leverage plus legacy underperformance increases vulnerability to currency, regulatory and funding shocks and limits long‑term value creation.
Aspen Pharmacare (APNHY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.67B
Dividend Yield2.15%
Average Volume (3M)710.00
Price to Earnings (P/E)―
Beta (1Y)0.23
Revenue Growth-0.03%
EPS Growth-123.67%
CountryUS
Employees8,867
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.19
Shares Outstanding446,252,320
10 Day Avg. Volume0
30 Day Avg. Volume710
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.63
Price to Sales (P/S)1.23
P/FCF Ratio512.59
Enterprise Value/Market Cap24.73
Enterprise Value/Revenue2.09
Enterprise Value/Gross Profit4.74
Enterprise Value/Ebitda33.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.82
Revenue Forecast (FY)$2.71B
Aspen Pharmacare Business Overview & Revenue Model
Company DescriptionAspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
How the Company Makes MoneyAspen Pharmacare generates revenue primarily through the sale of pharmaceutical products across various therapeutic categories. Its revenue model is built on three main streams: prescription medicines, consumer healthcare products, and active pharmaceutical ingredients. The company benefits from a robust distribution network that allows it to reach markets across Africa, Europe, and Asia-Pacific. Strategic partnerships and collaborations with other pharmaceutical companies enhance its product offerings and market presence. Additionally, Aspen's focus on generic pharmaceuticals allows it to compete effectively in price-sensitive markets, further contributing to its earnings. Factors such as regulatory approvals, successful product launches, and the expansion of its manufacturing capabilities also play significant roles in driving revenue growth.
Aspen Pharmacare Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Sep 02, 2026
Earnings Call Sentiment Neutral
The call conveys a balanced picture: strong operational cash generation, clear commercial pharma momentum (notably GLP‑1 traction), and a material APAC divestment that should materially strengthen the balance sheet and unlock shareholder value. Offsetting these positives are significant near‑term manufacturing and sterile segment setbacks (large EBITDA and revenue hits from lost contracts), a meaningful short‑term decline in group earnings, and ongoing macro/regulatory and currency risk. Management presented a defined recovery plan (cost reshaping, contract commercialization, insulin ramp, French site wins and sterile restructuring) and targets FY27 restoration of prior EBITDA levels, but execution is required to convert the improvements signaled into sustainable results.Q2-2026 Updates
Positive Updates
Strong free cash flow generation
Cash from operations ZAR 3.6bn (up from ZAR 1.8bn prior half); CapEx reduced to ZAR 1.6bn (from ZAR 2.6bn), producing ~ZAR 2bn of free cash flow for the half. Cash generation aided by lower working capital, lower cash finance costs and tax timing optimization.
Commercial Pharma growth and margin expansion
Commercial Pharma revenue +4% constant exchange rate (CER) and EBITDA +11% CER; EBITDA margin improved to 29.2% from 28.3%. All sub‑segments positive (Injectables +7% CER, Prescription +2% CER, OTC growth).
GLP‑1 momentum (Mounjaro & semaglutide opportunity)
South African GLP‑1 market ~ZAR 2.2bn (tripled in ~18 months); Mounjaro share rose from 21% to 52%. Management expects Mounjaro sales >ZAR 1.3bn in the period and continued rollout in Sub‑Saharan Africa; semaglutide generic entry targeted as early as calendar Q2 (Canada) with broader emerging‑market opportunity through 2026–2027.
APAC divestment to unlock material value and reduce debt
Transaction consideration AUD 237m (previously guided ~ZAR 26.5bn at AUD/ZAR ~11.05); assets held for sale NBV ZAR 21.8bn. Expected net proceeds >ZAR 25bn to be used primarily to reduce or extinguish net debt; anticipated after‑tax profit on sale ~ZAR 1.8–2.0bn to be recognized in H2 and interest savings ~ZAR 1.2bn pretax (c. ZAR 0.9bn after tax).
Operational recovery actions and commercial opportunities
Reshape largely complete (~90%); insulin contract started (ramp into FY27) and French facility RFQs increased from 1 to 6 with incremental secured volumes expected to add ~ZAR 300m EBITDA in FY27. Management target: recover lost EBITDA and reach positive sterile EBITDA by FY27.
ESG and access progress
Critical medicines volumes +8% vs FY24; women in top leadership 32% (from 19% in FY20); Scope 1 & 2 emissions down ~24% vs FY20 baseline; renewable energy usage ~19% across facilities; vaccine regulatory progress with two products registered with SAHPRA and expected further registrations in the next 9–12 months.
Negative Updates
Manufacturing segment collapse driven by mRNA contract loss
Manufacturing revenue down ~26% CER and EBITDA down ~85% (from ~ZAR 1.3bn to ~ZAR 0.2bn). Loss of the mRNA contract (~ZAR 1.5bn benefit prior year) plus settlement (~ZAR 500m) produced ~ZAR 1bn adverse swing to H1 EBITDA.
Group earnings and profitability decline
Group revenue ~ZAR 21bn (reported -4% vs prior year); normalized EBITDA ZAR ~5.05bn (down 13%); normalized headline earnings ZAR 5.75 (down 21%). Declines driven largely by Manufacturing/steriles disruption despite Commercial Pharma strength.
Gross margin dilution from weak manufacturing mix
Group gross profit margin fell from 47.6% to 45.4% (a ~7% decline in CER), while Commercial Pharma gross margins remained stable at ~58.5% — dilution primarily due to manufacturing underperformance.
Sterile business loss and recovery required
Sterile business reported losses and is dragging group profitability; management indicated API profits offset losses above a notional ZAR 1.7bn threshold and expects sterile EBITDA to reach breakeven or better by FY27 after restructuring and new contracts.
Return on invested capital (ROIC) weakness
Management acknowledged a concerning historical decline in ROIC. Large write‑downs/underperformance in parts of manufacturing/steriles have depressed returns, and improving ROIC is a stated priority.
Near‑term balance sheet and macro risks
Net debt remains elevated at ZAR 28.6bn (down from ZAR 31.2bn but still c.3.4x leverage). Results and reported rand figures are sensitive to currency (strong rand headwind). Regulatory, tariff and vaccine funding uncertainties and timing (e.g., WHO prequalification timing, tariffs, and macro volatility) remain risks until addressed.
Company Guidance
Guidance focused on a stronger H2 and FY26 driven by Commercial Pharma and cash generation: Commercial Pharma is guided to mid‑single‑digit revenue growth and double‑digit constant‑currency EBITDA growth (H1 Commercial Pharma: +4% revenue CER, +11% EBITDA CER, EBITDA margin 29.2%); Manufacturing is guided to be broadly in line with prior year as the group recoups the ~ZAR1.0bn lost contract contribution (H1 Manufacturing: revenue -26% CER, EBITDA down ~85% to ~ZAR0.2bn) and Steriles are targeted to reach EBITDA breakeven or better by FY27. Group targets include at least double‑digit normalized HEPS growth and a much stronger H2 (H1 group revenue ~ZAR21bn, normalized EBITDA ~ZAR5.05bn, continuing‑ops H1 EBITDA ~ZAR3.8bn; normalized HEPS H1 ZAR5.75, -21%); cash metrics are improving (cash from operations H1 ZAR3.6bn, CapEx H1 ZAR1.6bn, free cash flow ≈ZAR2bn for the half), net debt reduced to ZAR28.6bn (leverage ~3.4x) and, subject to the APAC divestment (AUD237m gross ≈ ZAR26.5–27bn; assets held for sale ~ZAR21.8bn; expected net proceeds >ZAR25bn), the group expects most debt to be eliminated, an H2 profit on sale of c.ZAR1.8–2.0bn and a net after‑tax impact (net of interest savings) of ~ZAR0.85bn, with a goal to restore group EBITDA to about ZAR9.6bn by FY27.Aspen Pharmacare Financial Statement Overview
Summary
Weak operating performance and cash conversion weigh heavily: revenue declined (-4.75%), net margin is negative (-2.50%), and free cash flow growth fell sharply (-96.22%). The balance sheet is relatively steadier with moderate leverage (debt-to-equity 0.43) and a strong equity ratio (62.45%), but negative ROE (-1.28%) reinforces profitability pressure.Income Statement
Aspen Pharmacare's income statement reveals a challenging year with a revenue decline of 4.75% and a negative net profit margin of -2.50% in the latest period. The gross profit margin remains relatively stable at 44.11%, indicating efficient cost management. However, the significant drop in EBIT and EBITDA margins from previous years highlights operational challenges. The company needs to address its declining revenue and profitability to improve its financial health.45
Neutral
Balance Sheet
The balance sheet shows a moderate debt-to-equity ratio of 0.43, suggesting a balanced approach to leveraging. However, the negative return on equity of -1.28% indicates that the company is not generating sufficient returns on its equity investments. The equity ratio of 62.45% reflects a strong equity base, providing some stability amidst financial challenges.60
Neutral
Cash Flow
Aspen Pharmacare's cash flow statement indicates a severe decline in free cash flow growth by 96.22%, raising concerns about cash generation capabilities. The operating cash flow to net income ratio of 0.29 suggests that cash flow is not adequately supporting net income, while the free cash flow to net income ratio of 0.02 is alarmingly low. The company needs to improve its cash flow management to ensure liquidity and operational sustainability.40
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 43.36B | 44.71B | 40.71B | 38.61B | 37.77B |
| Gross Profit | 19.13B | 19.42B | 18.41B | 18.31B | 17.79B |
| EBITDA | 2.16B | 9.90B | 10.19B | 9.93B | 8.67B |
| Net Income | -1.08B | 4.40B | 5.23B | 6.49B | 4.81B |
Balance Sheet | |||||
| Total Assets | 135.89B | 139.16B | 134.28B | 111.38B | 109.68B |
| Cash, Cash Equivalents and Short-Term Investments | 6.41B | 12.34B | 10.91B | 6.18B | 8.55B |
| Total Debt | 36.12B | 36.46B | 29.28B | 22.25B | 24.87B |
| Total Liabilities | 51.00B | 54.29B | 48.05B | 40.43B | 44.06B |
| Stockholders Equity | 84.89B | 84.86B | 86.24B | 70.94B | 65.63B |
Cash Flow | |||||
| Free Cash Flow | 104.00M | 690.00M | 2.34B | 2.68B | 3.39B |
| Operating Cash Flow | 5.16B | 6.22B | 5.52B | 5.37B | 6.83B |
| Investing Cash Flow | -5.22B | -9.47B | -3.42B | -2.16B | 9.76B |
| Financing Cash Flow | -162.00M | 3.62B | -420.00M | -4.68B | -15.65B |
Aspen Pharmacare Technical Analysis
Positive
6.80
Price Trends
7.17
Positive
6.40
Positive
6.33
Positive
Market Momentum
0.42
Negative
72.94
Negative
71.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APNHY, the sentiment is Positive. The current price of 6.8 is below the 20-day moving average (MA) of 7.71, below the 50-day MA of 7.17, and above the 200-day MA of 6.33, indicating a bullish trend. The MACD of 0.42 indicates Negative momentum. The RSI at 72.94 is Negative, neither overbought nor oversold. The STOCH value of 71.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APNHY.
Aspen Pharmacare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $3.14B | -72.78 | -3.68% | ― | 4.54% | -130.59% | |
58 Neutral | $3.67B | -49.22 | -1.18% | 2.15% | -0.03% | -123.67% | |
54 Neutral | $4.19B | 54.80 | ― | ― | 9.50% | ― | |
52 Neutral | $2.36B | 2.89 | 47.54% | ― | -1.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.61B | -1.35 | -38.66% | 8.48% | -2.55% | 66.00% | |
42 Neutral | $1.16B | -117.81 | ― | ― | 55.38% | ― |
* Healthcare Sector Average
APNHY
Aspen Pharmacare
8.59
-0.94
-9.84%
PRGO
Perrigo Company
11.20
-15.35
-57.81%
SUPN
Supernus Pharmaceuticals
54.27
22.45
70.55%
HCM
HUTCHMED
13.85
-2.17
-13.55%
AMRX
Amneal Pharmaceuticals
13.26
4.50
51.37%
ALVO
Alvotech
4.16
-6.97
-62.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.